Savara Inc
SVRADrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How SVRA's past catalysts played out
Molgramostim
Autoimmune Pulmonary Alveolar Proteinosis
Inhaled molgramostim
Mycobacterium Infections, Nontuberculous
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Molgramostim | Phase 3 | Autoimmune Pulmonary Alveolar Proteinosis | - | - |
Inhaled molgramostim | Phase 2 | Mycobacterium Infections, Nontuberculous | - | - |
Frequently asked questions
What is in Savara Inc's drug pipeline?→
CatalystAlert tracks 2 drug candidates in Savara Inc's (SVRA) pipeline across Phase 3, Phase 2. Its lead program is Molgramostim (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Savara Inc's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Savara Inc (SVRA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track SVRA biotech catalysts?→
Add SVRA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Savara Inc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.